Lyell Immunopharma, Inc. (LYEL)
9.17
-0.09
(-0.97%)
USD |
NASDAQ |
Oct 05, 09:35
Lyell Immunopharma Net Income (Quarterly) : -44.76M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.76M |
| March 31, 2026 | -24.15M |
| December 31, 2025 | -140.72M |
| September 30, 2025 | -38.85M |
| June 30, 2025 | -42.68M |
| March 31, 2025 | -52.20M |
| December 31, 2024 | -191.94M |
| September 30, 2024 | -44.58M |
| June 30, 2024 | -45.81M |
| March 31, 2024 | -60.67M |
| December 31, 2023 | -52.93M |
| September 30, 2023 | -50.85M |
| June 30, 2023 | -63.89M |
| Date | Value |
|---|---|
| March 31, 2023 | -66.96M |
| December 31, 2022 | -8.397M |
| September 30, 2022 | -70.25M |
| June 30, 2022 | -36.32M |
| March 31, 2022 | -68.14M |
| December 31, 2021 | -83.71M |
| September 30, 2021 | -48.88M |
| June 30, 2021 | -62.60M |
| March 31, 2021 | -55.04M |
| December 31, 2020 | -38.86M |
| September 30, 2020 | -35.72M |
| June 30, 2020 | -100.66M |
| March 31, 2020 | -29.24M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.004M |
| Total Expenses (Quarterly) | 44.76M |
| EPS Diluted (Quarterly) | -1.916 |
| Enterprise Value | 59.15M |
| Gross Profit Margin (Quarterly) | -55.45K% |
| Profit Margin (Quarterly) | -1.12M% |
| Earnings Yield | -128.3% |
| Normalized Earnings Yield | -107.03 |